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ABSTRACT
Stroke is a rare but serious complication of acute myocardial infarction (AMI). Currently, glycoprotein (GP) IIb/IIIa inhibi-
tor is used in clinical practice for acute coronary syndromes and percutaneous coronary interventions (PCIs). The incidence 
of stroke in patients receiving GP IIb/IIIa inhibitor during PCIs is very low. We report the case of a 47-year-old man who 
presented with AMI and suffered an acute cerebral infarction after infusion of a GP IIb/IIIa inhibitor following primary 
PCI. (Korean Circ J 2011;41:546-548)
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Introduction
Stroke is a rare but serious complication of acute myocar-
dial infarction (AMI). The incidence of in-hospital stroke 
complicating AMI is approximately 1%.
1) Hemorrhagic st-
roke during the first 24 hours is a well-known consequence 
of thrombolytic therapy. However, even without thromboly-
tic intervention, both hemorrhagic and ischemic strokes have 
been documented as complications of AMI and its treatment 
with anticoagulants.
2) 
Glycoprotein (GP) IIb/IIIa inhibitors are currently used in 
clinical practice for acute coronary syndrome and percuta-
neous coronary intervention (PCI). The incidence of stroke 
in patients receiving GP IIb/IIIa inhibitor during PCI is very 
low. Abciximab in addition to aspirin and heparin does not 
increase the risk of stroke in patients undergoing PCI.
3) We 
report here the case of a 47-year-old man who presented with 
AMI and suffered from an acute cerebral ischemic stroke after 
infusion of a GP IIb/IIIa inhibitor following primary PCI.
Case
A 47-year-old male presented to the emergency department 
at our hospital with prolonged chest pain. Electrocardigraphy 
revealed ST elevation in lead II, III, and aVF (Fig. 1). Trans-
thoracic echocardiography, which was performed when the 
patient arrived at the hospital, demonstrated hypokinesia of 
the inferior wall, preserved systolic function (ejection frac-
tion=50%), no thrombi in the cardiac chambers and no struc-
tural abnormalities. The patient was diagnosed as having ST-
elevation myocardial infarction and underwent primary PCI.
Coronary angiography revealed total occlusion of distal 
right coronary artery with a large occlusive thrombus (B2, 
100%, 0, 0) (Fig. 2). A 0.014 inch Runthrough
® guidewire (Te-
rumo, Tokyo, Japan) was passed across the stenotic lesion 
into the distal vessel. Thrombus aspiration was performed us-
ing an Export Aspiration Catheter (Medtronic, Minneapolis, 
MN, USA) by slowly advancing it during aspiration through 
the lesion. The lesion was then overlap-stented using a 4.0× 
23 mm everolimus-eluting stent at 15 atm and a 3.5×24 mm 
zotarolimus-eluting stent at 15 atm. The final coronary an-
giogram revealed Thrombolysis In Myocardial Infarction II 
flow with residual thrombus (Fig. 3), and GP IIb/IIIa inhibi-
tor infusion was initiated. Twelve hours after the infusion, the 
patient complained of left-sided weakness. Brain magnetic 
resonance imaging revealed foci of acute to hyperacute infarc-
tions in the right middle cerebral artery territory (Fig. 4). Tr-Woong Gil Choi, et al.   547
ansesophageal echocardiography demonstrated no right to 
left shunt flow and no thrombi in the cardiac chambers.
We suspected that systemic thrombolysis associated with 
intravenous GP IIb/IIIa inhibitor contributed to the fragment-
ation and lysis of a cardiac thrombus, which subsequently em-
bolized distally to block the cerebral circulation and cause ce-
rebral infarction.
Discussion 
Cerebrovascular events are well known complications that 
follow AMI, and although they rarely occur, they may have 
severe or long term adverse effects. 
A case-control study reported that the risk of stroke onset 
was highest shortly after AMI, and nearly 10 times higher 
than that of patients with stroke but without an MI. This risk 
declined rapidly to the rate of controls within several days.
4) 
This high risk was attributed to intracardiac thrombus forma-
tion, artery-to-artery embolism or in situ thrombosis, in the 
background of a prothrombotic state secondary to MI. In 
addition, older age, anterior site of MI, high enzyme levels, 
impaired left ventricular function, atrial arrhythmias, and pri-
or cerebrovascular disease were the most reliable predictors 
of stroke during AMI.
5) In the present case, although the pa-
tient had none of the risk factors mentioned above, cerebral 
infarction still occurred. 
GP IIb/IIIa inhibitors interfere with the final common path-
way to platelet aggregation, blocking receptors on activated 
platelets that bind fibrinogen molecules which form bridges 
between adjacent platelets. Thus, by competitive inhibition 
with fibrinogen, GP IIb/IIIa inhibitors could support endogen-
ous thrombolysis by reducing thrombus growth and prevent-
ing thrombus reformation. Although intravenous thromboly-
sis with recombinant tissue plasminogen activator is the only 
treatment with proven benefits on improved functional out-
come up to 4.5 hours from symptom onset in patients with 
acute ischemic stroke, a GP IIb/IIIa inhibitor might also be 
useful in patients with ischemic stroke.
6) The known compli-
Fig. 2. Coronary angiogram reveals total occlusion of distal right 
coronary artery with a large occlusive thrombus.
Fig. 3. Coronary angiogram after stent implantation demonstrates 
adequate luminal diameter of distal right coronary artery but re-
sidual thrombus.
Fig. 4. Brain magnetic resonance scan reveals acute ischemic in-
farction in the right middle cerebral artery territory after glycopro-
tein IIb/IIIa inhibitor infusion. A diffusion-weighted image reveals a 
region of hyperintensity in the distribution of the right middle cere-
bral artery (A). A T2-weighted image demonstrates a high signal 
intensity in the territory of the right middle cerebral artery (B).
Fig. 1. Twelve lead electrocardiography shows ST segment elev-
ation in lead II, III, and aVF.
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cations of GP IIb/IIIa inhibitor therapy are limited to hem-
orrhage, thrombocytopenia
7) and allergic reactions.
8) 
Although symptomatic intracerebral hemorrhage is a more 
common and severe side effect of the use of GP IIb/IIIa inhi-
bitors, in this case, ischemic stroke occurred after infusion of 
a GP IIb/IIIa inhibitor. The present case is unique in that the 
ischemic stroke occurred during GP IIb/IIIa inhibitor infu-
sion for AMI after primary PCI. The most likely mechanism 
is fragmentation of an intracardiac thrombus by the use of a 
GP IIa/IIIa inhibitor.
9) 
In conclusion, this case highlights that the administration 
of intravenous administration of a GP IIb/IIIa inhibitor may 
lead to fragmentation and lysis of an intracardiac thrombus 
with subsequent embolization to cerebral arteries and isch-
emic stroke. 
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